COVID-19 Vaccines Lower Risk of Heart Attack and Cardiac Death

ccording to three different studies, COVID-19 vaccines were associated with a lower risk of major adverse cardiovascular events (MACE), in addition to other outcomes, particularly among older adults.
Shingles Vaccine Reduces Risk of a Dementia Diagnosis

According to a cohort study using target trial emulation, older adults at higher risk for dementia are less likely to have a dementia diagnosis if they received a herpes zoster (shingles) vaccine.
IVIG Reduces Grade 2 Infections by 67 Percent in CLL

A study has found that intravenous immune globulin (IVIG) reduces grade 2 infections by 67 percent in patients with chronic lymphocytic leukemia.
Study Finds Flu Vaccine Sharply Reduces Infections in Children Ages 2 to 5

A study has found pediatric flu vaccines significantly reduce the number of childhood cases of influenza.
Cancer Vaccine Produces 49 Percent Melanoma Reduction in Patients

A study has found the combination of a vaccine and a drug, which both harness the immune system to attack cancer cells, is successful in cutting the risk of skin cancer recurrence and death by 49 percent.
Study Finds Moderna and Pfizer/BioNTech COVID-19 Vaccines 70 to 76 Percent Effective Against Severe Illness in Kids

A recent study in Taiwan that examined the vaccine effectiveness (VE) against moderate to severe COVID-19 infection in children aged 6 to 11 years found the Pfizer/BioNTech BNT162b2 VE was 69.9 percent and the Moderna mRNA-1273 VE was 75.5 percent during Omicron BA.2/BA.5 predominance in 2022.
Reduced Risk of Dementia Linked to Eight Vaccines

According to multiple large observational studies, the risk of dementia is associated with eight routine adult vaccines: the shingles, respiratory syncytial virus, influenza, DTP (diphtheria, tetanus and pertussis), pneumococcal, hepatitis A, hepatitis B and typhoid vaccines.
Takeda’s TAK-881 SCIG Product Meets Primary and Secondary Endpoints in Phase II/III Clinical Trial

Takeda’s pivotal Phase II/III clinical trial of its investigational TAK-881K SCIG 20% with recombinant human hyaluronidase) in patients with primary immunodeficiency met its primary and secondary endpoints.
FDA Approves Expanded Label for ASCENIV for PI Patients 2 Years and Older

The U.S. Food and Drug Administration has approved ADMA Biologics’ supplemental biologics license application to expand the prescribing information to primary humoral immunodeficiency indication to pediatric patients 2 years of age and older.
New Bill Introduced to Ensure Dedicated Payment for IVIG in Skilled Nursing Facilities

U.S. Representatives Adrian Smith (R-NE-03) and Doris Matsui (D-CA-07) have introduced the PI Post Acute Access Act to expand access to lifesaving care for individuals with primary immunodeficiencies